NuCana PLC at Oppenheimer Healthcare Conference (Virtual) Transcript
All right. Good afternoon, everyone. Welcome back to another session here at Oppenheimer's 33rd Annual Healthcare Conference. We're very delighted to have as our next presenting company, NuCana, which we cover with an outperform rating, and we are very excited about with respect to its multiple opportunities in oncology.
On behalf of the company, we have Chief Executive Officer, Hugh Griffith, who will be running through the business plan and the story.
And with that, I will turn the podium over to Hugh.
Good afternoon and a huge thank you to Leland and the wider Oppenheimer team for the invitation to present this afternoon. NuCana, the name, represents new cancer agents and specifically nucleotide analogs, and I'll come back to that in a minute. But I will be making some forward-looking statements as I go through this presentation. So I'd like to refer you to this disclaimer slide.
So what are we doing at NuCana? Well, we're
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |